Cautious Hold Rating on Sarepta Therapeutics Amid Promising but Inconclusive Sirolimus Findings

William Blair analyst Sami Corwin has maintained their neutral stance on SRPT stock, giving a Hold rating on October 8.

Sami Corwin has given his Hold rating due to a combination of factors related to Sarepta Therapeutics’ ongoing research and development efforts. The company recently presented findings at the World Muscle Society Congress, highlighting the potential of sirolimus in preventing acute liver injury (ALI) in patients treated with their gene therapy, Elevidys, for Duchenne muscular dystrophy (DMD). While early evidence suggests that sirolimus could be effective in mitigating ALI, the results are not yet statistically significant due to the small sample size, indicating that further research is needed to confirm these findings.
Sarepta’s efforts to incorporate sirolimus into their treatment protocol show promise, but the lack of conclusive data and the need for additional studies contribute to the cautious Hold rating. The expert committees’ recommendations for recognizing and preventing Elevidys-related ALI, including the use of sirolimus, are promising but require validation through larger clinical trials. As such, while there is potential for positive outcomes, the current uncertainties and the need for more robust data underpin the decision to maintain a Hold rating on Sarepta’s stock.

In another report released on October 8, RBC Capital also maintained a Hold rating on the stock with a $16.00 price target.